Search Results - "Peshkin, N."

Randomized Noninferiority Trial of Telephone Versus In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer by SCHWARTZ, Marc D, VALDIMARSDOTTIR, Heiddis B, MCKINNON, Wendy, GARBER, Judy, MCCORMICK, Shelley, KINNEY, Anita Y, LUTA, George, KELLEHER, Sarah, LEVENTHAL, Kara-Grace, VEGELLA, Patti, ANGIE TONG, LESLEY KING, PESHKIN, Beth N, MANDELBLATT, Jeanne, NUSBAUM, Rachel, HUANG, An-Tsun, YAOJEN CHANG, GRAVES, Kristi, ISAACS, Claudine, WOOD, Marie

“…Although guidelines recommend in-person counseling before BRCA1/BRCA2 gene testing, genetic counseling is increasingly offered by telephone. As genomic testing…”
Get full text

Attenuation of RNA polymerase II pausing mitigates BRCA1-associated R-loop accumulation and tumorigenesis by Zhang, Xiaowen, Chiang, Huai-Chin, Wang, Yao, Zhang, Chi, Smith, Sabrina, Zhao, Xiayan, Nair, Sreejith J., Michalek, Joel, Jatoi, Ismail, Lautner, Meeghan, Oliver, Boyce, Wang, Howard, Petit, Anna, Soler, Teresa, Brunet, Joan, Mateo, Francesca, Angel Pujana, Miguel, Poggi, Elizabeth, Chaldekas, Krysta, Isaacs, Claudine, Peshkin, Beth N., Ochoa, Oscar, Chedin, Frederic, Theoharis, Constantine, Sun, Lu-Zhe, Curiel, Tyler J., Elledge, Richard, Jin, Victor X., Hu, Yanfen, Li, Rong

“…Most BRCA1 -associated breast tumours are basal-like yet originate from luminal progenitors. BRCA1 is best known for its functions in double-strand break…”
Get full text

Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample by SINING CHEN, IVERSEN, Edwin S, CORIO, Camille, LEONDARIDIS, Leoni, TOMLINSON, Gail, DUTSON, Debra, KERBER, Rich, AMOS, Christopher I, STRONG, Louise C, BERRY, Donald A, EUHUS, David M, PARMIGIANI, Giovanni, FRIEBEL, Tara, FINKELSTEIN, Dianne, WEBER, Barbara L, EISEN, Andrea, PETERSON, Leif E, SCHILDKRAUT, Joellen M, ISAACS, Claudine, PESHKIN, Beth N

“…An accurate evaluation of the penetrance of BRCA1 and BRCA2 mutations is essential to the identification and clinical management of families at high risk of…”
Get full text

BRCA1/2 mutations and triple negative breast cancers by Peshkin, Beth N, Alabek, Michelle L, Isaacs, Claudine

“…Identifying breast cancer patients at increased risk for carrying a mutation in the BRCA1 and BRCA2 genes is an important objective in clinical practice…”
Get more information

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings by Smith, D. Max, Peshkin, Beth N., Springfield, T. Blaise, Brown, Ryan P., Hwang, Elizabeth, Kmiecik, Susanna, Shapiro, Richard, Eldadah, Zayd, Lundergan, Conor, McAlduff, Joel, Levin, Bonnie, Swain, Sandra M.

“…Most literature describing pharmacogenetic implementations are within academic medical centers and use single‐gene tests. Our objective was to describe the…”
Get full text

Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers by Walker, Logan C, Marquart, Louise, Pearson, John F, Wiggins, George A R, O'Mara, Tracy A, Parsons, Michael T, Barrowdale, Daniel, McGuffog, Lesley, Dennis, Joe, Benitez, Javier, Slavin, Thomas P, Radice, Paolo, Frost, Debra, Godwin, Andrew K, Meindl, Alfons, Schmutzler, Rita Katharina, Isaacs, Claudine, Peshkin, Beth N, Caldes, Trinidad, Hogervorst, Frans Bl, Lazaro, Conxi, Jakubowska, Anna, Montagna, Marco, Chen, Xiaoqing, Offit, Kenneth, Hulick, Peter J, Andrulis, Irene L, Lindblom, Annika, Nussbaum, Robert L, Nathanson, Katherine L, Chenevix-Trench, Georgia, Antoniou, Antonis C, Couch, Fergus J, Spurdle, Amanda B

“…Genome-wide studies of patients carrying pathogenic variants (mutations) in BRCA1 or BRCA2 have reported strong associations between single-nucleotide…”
Get full text

Impact of BRCA1/BRCA2 Counseling and Testing on Newly Diagnosed Breast Cancer Patients by SCHWARTZ, Marc D, CARYN LERMAN, PENNANEN, Marie, TSANGARIS, Theodore, WILLEY, Shawna, ISAACS, Claudine, BROGAN, Barbara, PESHKIN, Beth N, HALBERT, Chanita Hughes, DEMARCO, Tiffani, LAWRENCE, William, MAIN, David, FINCH, Clinton, MAGNANT, Colette

“…Approximately 5% to 10% of newly diagnosed breast cancer patients carry a BRCA1 or BRCA2 mutation. Given these patients' high risk for contralateral breast…”
Get full text

BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes by BERRY, Donald A, IVERSEN, Edwin S, RUBINSTEIN, Wendy S, HUGHES, Kevin S, PARMIGIANI, Giovanni, GUDBJARTSSON, Daniel F, HILLER, Elaine H, GARBER, Judy E, PESHKIN, Beth N, LERMAN, Caryn, WATSON, Patrice, LYNCH, Henry T, HILSENBECK, Susan G

“…To compare genetic test results for deleterious mutations of BRCA1 and BRCA2 with estimated probabilities of carrying such mutations; to assess sensitivity of…”
Get full text

Results of a randomized controlled trial of a decision support intervention for disclosing maternal BRCA genetic test results to children and adolescents by Tercyak, Kenneth P., DeMarco, Tiffani A., Schneider, Katherine A., Luta, George, Isaacs, Claudine, Garber, Judy E., Sleiman, Marcelo M., Yockel, Mary Rose, Peshkin, Beth N.

“…Evaluate the impact of a targeted family communication intervention for mothers undergoing genetic counseling and testing (GCT) for BRCA gene alterations…”
Get full text

Improving our model of cascade testing for hereditary cancer risk by leveraging patient peer support: a concept report by O'Neill, Suzanne C, Hamilton, Jada G, Conley, Claire C, Peshkin, Beth N, Sacca, Rosalba, McDonnell, Glynnis A, Isaacs, Claudine, Robson, Mark E, Tercyak, Kenneth P

“…Consensus and evidence suggest that cascade testing is critical to achieve the promise of cancer genetic testing. However, barriers to cascade testing include…”
Get full text

Bilateral Prophylactic Oophorectomy and Ovarian Cancer Screening Following BRCA1/BRCA2 Mutation Testing by SCHWARTZ, Marc D, KAUFMAN, Elizabeth, PESHKIN, Beth N, ISAACS, Claudine, HUGHES, Chanita, DEMARCO, Tiffani, FINCH, Clinton, LERMAN, Caryn

“…Despite the widespread availability of genetic testing for BRCA1/BRCA2 mutations, little is known about the impact of testing on ovarian cancer prevention and…”
Get full text

A Brief Assessment of Concerns Associated With Genetic Testing for Cancer: The Multidimensional Impact of Cancer Risk Assessment (MICRA) Questionnaire by Cella, David, Hughes, Chanita, Peterman, Amy, Chang, Chih-Hung, Peshkin, Beth N, Schwartz, Marc D, Wenzel, Lari, Lemke, Amy, Marcus, Alfred C, Lerman, Caryn

“…The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a new tool to measure the specific impact of result disclosure after genetic testing. The…”
Get full text

Impact of BRCA1/BRCA2 Mutation Testing on Psychologic Distress in a Clinic-Based Sample by Schwartz, M. D.

Get full text

Quality of Life After Contralateral Prophylactic Mastectomy in Newly Diagnosed High-Risk Breast Cancer Patients Who Underwent BRCA1/2 Gene Testing by TERCYAK, Kenneth P, PESHKIN, Beth N, BROGAN, Barbara M, DEMARCO, Tiffani, PENNANEN, Marie F, WILLEY, Shawna C, MAGNANT, Colette M, ROGERS, Sarah, ISAACS, Claudine, SCHWARTZ, Marc D

“…Recent studies indicate that high-risk breast cancer patients (ie, women who carry mutations in BRCA1/2 genes) who opt for contralateral prophylactic…”
Get full text

Utilization of BRCA1/BRCA2 Mutation Testing in Newly Diagnosed Breast Cancer Patients by SCHWARTZ, Marc D, LERMAN, Caryn, BROGAN, Barbara, PESHKIN, Beth N, ISAACS, Claudine, DEMARCO, Tiffani, HALBERT, Chanita Hughes, PENNANEN, Marie, FINCH, Clinton

“…Background: Among newly diagnosed breast cancer patients who are at risk for carrying a BRCA1 or BRCA2 mutation, knowledge of mutation status can influence…”
Get full text

Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support by Evans, Chalanda, Hamilton, Rebekah J, Tercyak, Kenneth P, Peshkin, Beth N, Rabemananjara, Kantoniony, Isaacs, Claudine, O'Neill, Suzanne C

“…Young women from hereditary breast and ovarian cancer (HBOC) families face a series of medical decisions regarding their cancer risk management and integrating…”
Get full text

Prognostic Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Radiation Therapy by Kumar, S, Movsas, B, Brown, S.L, Simoff, M, Stone, C.H, Jenrow, K.A, Lapanowski, K, Ajlouni, M, Chetty, I.J, Movsas, A, Lu, M, Sitarik, A, Lamerato, L, Jones, M.R, Hammoud, Z, Peshkin, N, Roszka, K, Parry, R

Get full text

Diffusion tensor tomography with tractography in assessment of the pyramidal system in patients with highly active multiple sclerosis by Peshkin, A. N., Toniya, G. T., Stepanova, E. A., Lizhdvoi, V. Yu, Kotov, S. V.

“…Objective : to study the pyramidal tract in patients with highly active multiple sclerosis (HAMS) during treatment switching from first-line MS therapy to…”
Get full text

What Would You Do? Specialists’ Perspectives on Cancer Genetic Testing, Prophylactic Surgery, and Insurance Discrimination by MATLOFF, E. T, SHAPPELL, H, BRIERLEY, K, BERNHARDT, B. A, MCKINNON, W, PESHKIN, B. N

“…To examine what cancer genetics specialists predict they would do personally if they were at 50% risk of carrying a mutation that predisposes to hereditary…”
Get full text

Prognostic Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Radiation Therapy by Kumar, S, Movsas, B, Brown, S.L, Simoff, M, Stone, C.H, Jenrow, K.A, Lapanowski, K, Ajlouni, M, Chetty, I.J, Movsas, A, Lu, M, Sitarik, A, Lamerato, L, Jones, M.R, Hammoud, Z, Peshkin, N, Roszka, K, Parry, R

Get full text